Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab plus carboplatin-based chemotherapy versus carboplatin-based chemotherapy in platinum-sensitive recurrent ovarian cancer
2005-000557-30Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pertuzumab in ovarian cancer (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Jul 2005; status: completed.
02
Drugs
pertuzumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2005-000557-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000557-30.